Atherosclerotic Cardiovascular DiseaseFLARENCT07160829
Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure Management
An observational study of Atherosclerotic Cardiovascular Disease and Heart Failure, run by Novo Nordisk A/S at 4 sites in 4 countries.
Trial summary
This is a survey-based study conducted among cardiologists and nephrologists treating people with Atherosclerotic Cardiovascular Disease (ASCVD), Heart Failure (HF) and Chronic Kidney Disease (CKD). Study participants will be recruited to complete self-administered online survey. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atherosclerotic Cardiovascular Disease, Heart Failure, Chronic Kidney Disease
- What is being tested?
- No treatment given
- How many people
- 608 participants
- Where
- 4 sitesin 4 countries
- Study dates
- 18 Sep 2025to 30 Oct 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population includes cardiologists and nephrologists treating people with Atherosclerotic Cardiovascular Disease (ASCVD), Heart Failure (HF) and Chronic Kidney Disease (CKD)
Who may be able to join
- Informed consent obtained before any study related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Male or female, age above 18 years at the time of signing informed consent.
- Is a nephrologist or cardiologist. Cardiologists may be a mix of Interventional Cardiology, Heart Failure (HF) Specialist, General Cardiology, Preventative Cardiology, Cardiac Electrophysiology, Cardio-Oncology or Echocardiography (India only).
- Has been in specialty practice greater than or equal to 3 years.
- If cardiologist, sees at least 15 people with Atherosclerotic Cardiovascular Disease (ASCVD) with or without Chronic Kidney Disease (CKD) per month.
- If nephrologist, sees at least 20 people with ASCVD and CKD per month.
Who cannot join
- Previous participation in this study. Participation is defined as having given informed consent in this study.
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- If nephrologist, is only using dialysis to treat people with ASCVD and CKD.
- Does not meet inclusion criteria requirements.
Trial locations and contacts
4 sites in 4 countries.
4 sites in 4 countries
About this study
This is a survey-based study conducted among cardiologists and nephrologists treating people with Atherosclerotic Cardiovascular Disease (ASCVD), Heart Failure (HF) and Chronic Kidney Disease (CKD). Study participants will be recruited to complete self-administered online survey. The purpose of this research is to gather real-world evidence related to attitudes around systemic inflammation and specifically the awareness, perception, drivers and barriers, and use of hsCRP in clinical practice to identify systemic inflammation in people with ASCVD+CKD and HF.
- Being tested
- No treatment given
- Medical subject headings
- Atherosclerosis, Heart Failure, Renal Insufficiency, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No treatment givenOther
No treatment given
| Study group | Role | What they receive |
|---|---|---|
| Nephrologist Group | This group includes nephrologists treating people with ASCVD and CKD. Receives: Other: No treatment given | |
| Cardiologist Group | This group includes cardiologist treating people with ASCVD and CKD. Receives: Other: No treatment given |
What is being measured
The primary outcome is the main question the study is designed to answer.
Perceptions towards role of systemic inflammation in identification, treatment, management of ASCVD+CKD and HF
Multi-select from a defined list; 7-point Likert scale where 1=Not at all Important and Single-select from a defined list; Numerical; 7=Extremely Important; 7-point Likert scale where 1=Strongly Disagree and 7=Strongly Agree.
Cardiologists and nephrologists' perceptions towards the role of systemic inflammation in the identification, treatment and management of people with Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease (ASCVD+CKD) and Heart Failure (HF)
Measured: At the time of survey response (Day 1)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2025
- Study start18 Sep 2025
- Primary completion30 Oct 2025
- Study completion30 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atherosclerotic Cardiovascular DiseaseStudies of the same condition, open and under way.
- More trials run by Novo Nordisk A/SThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 608 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Transparency dept. 2834, Study director, Novo Nordisk A/S
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07160829
- Sponsor's protocol ID
- DAS-8416
- Other IDs
- U1111-1315-0755
- Acronym
- FLARE
- Status last verified
- Feb 2026
- First submitted
- 29 Aug 2025
- Last updated
- 11 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Study at a glance
From the registry record, last updated by the sponsor on 11 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure Management
- ClinicalTrials.gov ID
- NCT07160829
- Acronym / sponsor ID
- FLARE / DAS-8416
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 608 participants (actual)
- Lead sponsor
- Novo Nordisk A/SIndustry (pharma, biotech, devices)
- Study start
- 18 Sep 2025 (actual)
- Primary completion
- 30 Oct 2025 (actual)
- Study completion
- 30 Oct 2025 (actual)
- First posted
- 8 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a survey-based study conducted among cardiologists and nephrologists treating people with Atherosclerotic Cardiovascular Disease (ASCVD), Heart Failure (HF) and Chronic Kidney Disease (CKD). Study participants will be recruited to complete self-administered online survey. The purpose of this research is to gather real-world evidence related to attitudes around systemic inflammation and specifically the awareness, perception, drivers and barriers, and use of hsCRP in clinical practice to identify systemic inflammation in people with ASCVD+CKD and HF.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Nephrologist Group | – | Other: No treatment givenThis group includes nephrologists treating people with ASCVD and CKD. |
| Cardiologist Group | – | Other: No treatment givenThis group includes cardiologist treating people with ASCVD and CKD. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population includes cardiologists and nephrologists treating people with Atherosclerotic Cardiovascular Disease (ASCVD), Heart Failure (HF) and Chronic Kidney Disease (CKD)
Key inclusion criteria (6 listed)
- Informed consent obtained before any study related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Male or female, age above 18 years at the time of signing informed consent.
- Is a nephrologist or cardiologist. Cardiologists may be a mix of Interventional Cardiology, Heart Failure (HF) Specialist, General Cardiology, Preventative Cardiology, Cardiac Electrophysiology, Cardio-Oncology or Echocardiography (India only).
- Has been in specialty practice greater than or equal to 3 years.
- If cardiologist, sees at least 15 people with Atherosclerotic Cardiovascular Disease (ASCVD) with or without Chronic Kidney Disease (CKD) per month.
Key exclusion criteria (4 listed)
- Previous participation in this study. Participation is defined as having given informed consent in this study.
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- If nephrologist, is only using dialysis to treat people with ASCVD and CKD.
- Does not meet inclusion criteria requirements.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No treatment givenNo treatment given | Other | Cardiologist Group, Nephrologist Group |
Primary outcome
Perceptions towards role of systemic inflammation in identification, treatment, management of ASCVD+CKD and HF
Time frame: At the time of survey response (Day 1)
Multi-select from a defined list; 7-point Likert scale where 1=Not at all Important and Single-select from a defined list; Numerical; 7=Extremely Important; 7-point Likert scale where 1=Strongly Disagree and 7=Strongly Agree. Cardiologists and nephrologists' perceptions towards the role of systemic inflammation in the identification, treatment and management of people with Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease (ASCVD+CKD) and Heart Failure (HF)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Feb 2026.
- Individual participant dataSharing planned: Yes. According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Related trials for Atherosclerotic Cardiovascular Disease
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Active, not recruiting
SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study
Peripheral Artery Disease
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
RecruitingPhase 3
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Peripheral Artery Disease (PAD)
Recruiting
The THOR IDE Study
Peripheral Artery Disease, Peripheral Artery Stenosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Transparency dept. 2834 study director
Novo Nordisk A/S
4 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atherosclerotic Cardiovascular Disease and Heart Failure, run by Novo Nordisk A/S at 4 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Australia, India, South Korea, Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Perceptions towards role of systemic inflammation in identification, treatment, management of ASCVD+CKD and HF (time frame: At the time of survey response (Day 1)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2026.